Osher Van de Voorde Investment Management lessened its stake in Medtronic plc (NYSE:MDT – Free Report) by 0.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 207,515 shares of the medical technology company’s stock after selling 550 shares during the quarter. Medtronic makes up approximately 4.0% of Osher Van de Voorde Investment Management’s portfolio, making the stock its 15th biggest holding. Osher Van de Voorde Investment Management’s holdings in Medtronic were worth $18,683,000 at the end of the most recent reporting period.
A number of other hedge funds also recently modified their holdings of the stock. Boyar Asset Management Inc. lifted its holdings in shares of Medtronic by 2.6% during the 4th quarter. Boyar Asset Management Inc. now owns 4,655 shares of the medical technology company’s stock valued at $383,000 after buying an additional 120 shares during the period. Quent Capital LLC increased its stake in shares of Medtronic by 8.0% in the 1st quarter. Quent Capital LLC now owns 1,680 shares of the medical technology company’s stock worth $146,000 after purchasing an additional 125 shares in the last quarter. Abbrea Capital LLC increased its stake in shares of Medtronic by 2.5% in the 1st quarter. Abbrea Capital LLC now owns 5,077 shares of the medical technology company’s stock worth $446,000 after purchasing an additional 125 shares in the last quarter. Waterway Wealth Management LLC increased its stake in shares of Medtronic by 4.8% in the 2nd quarter. Waterway Wealth Management LLC now owns 2,759 shares of the medical technology company’s stock worth $217,000 after purchasing an additional 126 shares in the last quarter. Finally, Americana Partners LLC increased its stake in shares of Medtronic by 2.0% in the 2nd quarter. Americana Partners LLC now owns 6,667 shares of the medical technology company’s stock worth $525,000 after purchasing an additional 128 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.
Medtronic Trading Up 1.3 %
Shares of Medtronic stock opened at $88.14 on Wednesday. The firm has a market cap of $113.02 billion, a price-to-earnings ratio of 32.05, a PEG ratio of 2.56 and a beta of 0.84. The business has a 50-day moving average price of $87.06 and a 200-day moving average price of $83.35. The company has a quick ratio of 1.61, a current ratio of 2.13 and a debt-to-equity ratio of 0.55. Medtronic plc has a twelve month low of $68.84 and a twelve month high of $91.49.
Medtronic Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 11th. Investors of record on Friday, September 27th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Friday, September 27th. Medtronic’s payout ratio is 101.82%.
Analyst Upgrades and Downgrades
Several research firms have recently commented on MDT. Truist Financial upped their price objective on Medtronic from $85.00 to $90.00 and gave the stock a “hold” rating in a research note on Friday, August 23rd. Citigroup upped their price objective on Medtronic from $85.00 to $92.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. Royal Bank of Canada upped their price objective on Medtronic from $92.00 to $98.00 and gave the stock a “sector perform” rating in a research note on Tuesday. Piper Sandler increased their price target on Medtronic from $85.00 to $90.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 21st. Finally, Oppenheimer increased their price target on Medtronic from $92.00 to $94.00 and gave the stock a “market perform” rating in a research note on Wednesday, August 21st. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Medtronic presently has a consensus rating of “Hold” and a consensus target price of $94.64.
Get Our Latest Stock Report on MDT
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
See Also
- Five stocks we like better than Medtronic
- How to Use the MarketBeat Excel Dividend Calculator
- Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
- Canadian Penny Stocks: Can They Make You Rich?
- Pinterest: Time to Jump Onboard for Long-Term Gains?
- Dividend Payout Ratio Calculator
- 4 Best ETFs for Capitalizing on the Semiconductor Market Surge
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.